ATRX is a regulator of therapy induced senescence in human cells

Marta Kovatcheva; Will Liao; Mary E. Klein; Nicolas Robine; Heather Geiger; Aimee M. Crago; Mark A. Dickson; William D. Tap; Samuel Singer; Andrew Koff

doi:10.1038/s41467-017-00540-5

Nature Communications (Aug 2017)

ATRX is a regulator of therapy induced senescence in human cells

Marta Kovatcheva,
Will Liao,
Mary E. Klein,
Nicolas Robine,
Heather Geiger,
Aimee M. Crago,
Mark A. Dickson,
William D. Tap,
Samuel Singer,
Andrew Koff

Affiliations

Marta Kovatcheva: The Louis V. Gerstner Graduate School of Biomedical Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Will Liao: The New York Genome Center
Mary E. Klein: The Louis V. Gerstner Graduate School of Biomedical Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Nicolas Robine: The New York Genome Center
Heather Geiger: The New York Genome Center
Aimee M. Crago: Program in Molecular Biology, Memorial Sloan Kettering Cancer Center
Mark A. Dickson: Department of Medicine, Weill College of Medicine, Cornell University
William D. Tap: Department of Medicine, Weill College of Medicine, Cornell University
Samuel Singer: Department of Surgery, Memorial Sloan Kettering Cancer Center
Andrew Koff: The Louis V. Gerstner Graduate School of Biomedical Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center

DOI: https://doi.org/10.1038/s41467-017-00540-5
Journal volume & issue: Vol. 8, no. 1
pp. 1 – 16

Abstract

Read online

Therapy induced senescence (TIS) is a growth suppressive program activated by cytostatic agents in some cancer cells. Here the authors show that the chromatin remodeling enzyme ATRX is a regulator of TIS and drives cells into this state via multiple mechanisms.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal